Immuron Ltd
ASX:IMC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Immuron Ltd
Total Current Assets
Immuron Ltd
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immuron Ltd
ASX:IMC
|
Total Current Assets
AU$14.9m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
14%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Current Assets
$202.5m
|
CAGR 3-Years
37%
|
CAGR 5-Years
17%
|
CAGR 10-Years
4%
|
|
|
CSL Ltd
ASX:CSL
|
Total Current Assets
$11.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Current Assets
AU$21.2m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Current Assets
AU$330.3m
|
CAGR 3-Years
24%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Current Assets
AU$153.7m
|
CAGR 3-Years
81%
|
CAGR 5-Years
22%
|
CAGR 10-Years
32%
|
|
Immuron Ltd
Glance View
Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in technology platform focused on the development and commercialization of a novel polyclonal antibodies to treat unmet medical needs. The firm operates through two segments: Research and development (R&D) and Hyperimmune product. R&D segment focuses on R&D projects performed in Australia, Israel, and United States. Hyperimmune product segment is engaged in Travelan and Protectyn activities, which occurs in Australia, the Unites States and Canada. The firm's flagship products include Travelan & Protectyn. Travelan is an over the counter immune supplement that can be taken to reduce the risk of diarrhea and reduce the symptoms of minor gastrointestinal disorders. Protectyn is an anti-LPS antibodies, which target and remove harmful bacteria and LPS toxins in the gut. The firm focused on clinical development of three drug candidates and several in early-stage preclinical development.
See Also
What is Immuron Ltd's Total Current Assets?
Total Current Assets
14.9m
AUD
Based on the financial report for Dec 31, 2025, Immuron Ltd's Total Current Assets amounts to 14.9m AUD.
What is Immuron Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
14%
Over the last year, the Total Current Assets growth was 27%. The average annual Total Current Assets growth rates for Immuron Ltd have been -10% over the past three years , -11% over the past five years , and 14% over the past ten years .
